{
    "organizations": [],
    "uuid": "beb027ff45819c633aa5af358292eb3b600ff2aa",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-launches-ozempic-and/brief-novo-nordisk-launches-ozempic-and-fiasp-in-the-u-s-idUSC7N1O701K",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk Launches Ozempic And Fiasp In The U.S.",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - NOVO NORDISK:\n* SAYS LAUNCHES OZEMPIC AND FIASP IN THE UNITED STATES * BOTH DIABETES MEDICATIONS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION IN 2017 Further company coverage: (Copenhagen newsroom)\n ",
    "published": "2018-02-05T21:43:00.000+02:00",
    "crawled": "2018-02-06T23:45:56.046+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novo",
        "nordisk",
        "say",
        "launch",
        "ozempic",
        "fiasp",
        "united",
        "state",
        "diabetes",
        "medication",
        "received",
        "approval",
        "food",
        "drug",
        "administration",
        "company",
        "coverage",
        "copenhagen",
        "newsroom"
    ]
}